Morgan Stanley analyst Tejas Savant maintained a Hold rating on Illumina (ILMN – Research Report) today and set a price target of $136.00. The ...

Shares of genomics company Illumina (NASDAQ:ILMN) fell 8.6% in the morning session after the company reported fourth-quarter results and provided full-year revenue guidance, which fell below Wall ...

Shares of Illumina Inc. ILMN shed 5.47% to $104.99 Monday, on what proved to be an all-around favorable trading session for ...

A number of other analysts also recently weighed in on the company. Stephens upped their target price on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a ...

On Monday, for the second time in as many business days, Illumina ( ILMN -4.11%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% ...

We recently published a list of Jim Cramer Discusses These 10 Stocks & Dissects President Trump’s China Tariffs. In this ...

Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

However, 10 companies defied a broader market optimism, mostly due to a series of stock rating downgrades from investment ...

China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...